<DOC>
	<DOCNO>NCT00474851</DOCNO>
	<brief_summary>The purpose study determine whether regimen norethindrone acetate + placebo norethindrone acetate + conjugate estrogen superior maintain skeletal health quality life adolescent treat GnRH agonist endometriosis .</brief_summary>
	<brief_title>The Effect Hormonal Add-Back Therapy Adolescents Treated With GnRH Agonist Endometriosis : A Randomized Trial</brief_title>
	<detailed_description>Endometriosis become increasingly recognize chronic illness begin adolescence . Untreated endometriosis may lead chronic pain infertility . As recognition need prompt therapy increase , length time patient expose treatment . As result , exist press need evaluate adjunctive measure may limit associate negative health consequence treatment . A gonadotropin-releasing hormone ( GnRH ) agonist one medication utilized patient fail treatment . While GnRH-agonists effective relieving symptom , long-term use problematic . GnRH agonists induce low-estrogen state , cause deleterious effect bone mineralization . These negative consequence especially important pediatric patient . Adolescence critical period woman 's life bone acquisition attainment peak bone mass . Anything interfere process put patient risk lifelong low bone density future fracture . `` Add-back '' therapy appear promising adjunct treatment prevention bone loss . Daily therapy low-doses hormone preserve bone density adult patient , without alter efficacy GnRH-agonist . However , data exist effect add-back therapy adolescent . The aim current study evaluate safety efficacy two add-back regimen , norethindrone acetate + placebo norethindrone acetate + conjugate estrogen , preservation skeletal health quality life adolescent endometriosis treat GnRH-agonist .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>Age 1322 year , least two year postmenarche Body mass index ( BMI , kg/m2 ) 18 30 kg/m2 Surgical diagnosis endometriosis Clinical decision treat GnRH agonist , leuprolide depot ( Lupron DepotÂ® ; TAP Pharmaceuticals , Inc. ) 11.25 mg intramuscular every 3 month Concomitant chronic disease affect bone health , cystic fibrosis , inflammatory bowel disease , renal disease , diabetes mellitus Markedly impair liver function liver failure Personal history thromboembolic event ( deep venous thrombosis ) Medication use know affect bone metabolism : Glucocorticoid therapy ( include inhale steroid ) anticonvulsant use last 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Bone density</keyword>
	<keyword>GnRH Agonist</keyword>
	<keyword>Add-back therapy</keyword>
</DOC>